Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), headquartered in Charlottesville, VA with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company innovating in the field of Alzheimer's disease (AD) and other neurodegenerative disorders. Acumen's core focus is on the development of novel, disease-modifying treatments by targeting toxic soluble amyloid-beta oligomers (AβOs), which are believed to be a primary underlying cause of AD. The company’s lead therapeutic candidate, sabirnetug (ACU193), is a humanized monoclonal antibody designed to selectively target these AβOs, thereby preventing synaptic dysfunction and neurodegeneration.
Acumen's scientific founders are pioneers in AβO research, contributing to decades of understanding in the field. This extensive research has culminated in the development of sabirnetug, which demonstrated positive topline results from the Phase 1 INTERCEPT-AD clinical trial. The trial showed that sabirnetug is well-tolerated, with a favorable safety profile, and demonstrated statistically significant, dose-related amyloid plaque reduction, validating its proof-of-mechanism.
Currently, Acumen is advancing sabirnetug into the Phase 2 ALTITUDE-AD trial, which aims to further evaluate its clinical efficacy and safety in early Alzheimer's disease. The company is also planning a Phase 1 study to explore a subcutaneous dosing option, enhancing patient accessibility and treatment convenience.
Acumen Pharmaceuticals remains committed to advancing its pioneering research into practical therapeutic solutions. The company's strategic partnerships, including a recent collaboration with Lonza for the manufacturing of sabirnetug, underscore its dedication to bringing effective treatments to market. With a strong financial footing, including $296.6 million in cash and marketable securities as of March 31, 2024, Acumen is well-positioned to support its clinical and operational activities into the first half of 2027.
Acumen’s mission is driven by the urgent need for safe and effective treatment options for Alzheimer's patients. Their work continues to be fueled by robust scientific insights and a commitment to improving the lives of those afflicted by AD.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented research at the AD/PD 2023 conference showcasing a human model using iPSC-derived excitatory neurons to study drug binding to amyloid beta oligomers linked to Alzheimer’s disease (AD). Key findings indicate oligomer size affects neuronal binding, underscoring the significance of oligomer preparation and antibody selection in assays. This research supports Acumen's clinical development of ACU193, a monoclonal antibody targeting toxic globular sAβOs, with patient enrollment completed for its Phase 1 INTERCEPT-AD trial. The poster presentation is scheduled for March 28 and will be accessible throughout the conference.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial for ACU193, targeting early Alzheimer's disease, in February 2023, with topline results anticipated in Q3 2023. The company reported a cash balance of $193.4 million as of December 31, 2022, projected to sustain operations through 2025. R&D expenses surged to $32.4 million, up from $12.3 million in 2021, reflecting ongoing clinical trials. Despite a net loss of $42.9 million for 2022, a decrease from $100.6 million in 2021, the firm remains optimistic about its future developments, bolstered by FDA Fast Track designation for ACU193.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced its participation in a fireside chat at the Stifel 2023 Virtual CNS Days on March 29, 2023, at 12:30 p.m. ET. This event will showcase the company's novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease treatment. The live webcast will be accessible through the Investors tab on www.acumenpharm.com and will be archived for 14 days.
Acumen is advancing its investigational product candidate, ACU193, a monoclonal antibody in a Phase 1 clinical trial focused on early Alzheimer’s patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report its fourth quarter and year-end 2022 financial results on March 27, 2023. The company is focused on developing ACU193, a novel therapeutic targeting soluble amyloid beta oligomers for Alzheimer’s disease treatment. A conference call and live audio webcast will occur at 8:00 a.m. ET for a business and financial update. This important milestone is part of Acumen's efforts in advancing its investigational product candidate, which is currently in a Phase 1 clinical trial.
Acumen Pharmaceuticals (NASDAQ: ABOS), a biopharmaceutical company targeting Alzheimer's disease, will participate in the Needham Virtual Neuroscience Forum on March 15, 2023, at 10:00 a.m. ET. The company focuses on developing ACU193, a humanized monoclonal antibody aimed at combating toxic soluble amyloid beta oligomers, a key contributor to Alzheimer’s pathology. The live webcast can be accessed under the Investors tab on their website and will be available for 14 days post-event. Founded by researchers in amyloid beta oligomers, Acumen is advancing its Phase 1 clinical trial, INTERCEPT-AD, for early Alzheimer’s patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) has completed enrollment for its Phase 1 INTERCEPT-AD trial of ACU193, a monoclonal antibody targeting toxic soluble amyloid beta oligomers, aimed at treating Alzheimer’s disease. A total of 65 subjects were enrolled across 17 sites in the U.S. Results, including safety and proof-of-mechanism data, are expected by Q3 2023, earlier than anticipated. ACU193 is the first antibody developed to selectively target these oligomers, which are linked to neurodegeneration in Alzheimer’s.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced the appointment of Dr. Derrell Porter to its Board of Directors on January 4, 2023. Dr. Porter, a physician-entrepreneur with over 20 years of experience in drug development, will enhance Acumen’s strategic direction as it advances clinical trials for ACU193, a potential disease-modifying treatment for Alzheimer’s disease. This humanized monoclonal antibody targets toxic soluble AβOs, aiming to mitigate neurodegeneration associated with Alzheimer's. ACU193 has received Fast Track designation from the FDA.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
What is Acumen Pharmaceuticals’ main focus?
What is sabirnetug (ACU193)?
What were the results of the Phase 1 INTERCEPT-AD trial?
What is the Phase 2 ALTITUDE-AD trial?
What are some recent achievements of Acumen Pharmaceuticals?
What is Acumen’s financial condition?
Where is Acumen Pharmaceuticals headquartered?
What is the significance of targeting amyloid-beta oligomers (AβOs)?
What future plans does Acumen Pharmaceuticals have for sabirnetug?
How can investors get more information about Acumen Pharmaceuticals?
